SCHEMBL8446262

SCHEMBL8446262

COc1cc2c(=O)cc(C(=O)O)[nH]c2c2ncccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 2/20 0.48
GAA P10253 2/20 0.48
KDM4E B2RXH2 4/20 0.48
HPGD P15428 3/20 0.48
TDP1 Q9NUW8 1/20 0.47
GPR35 Q9HC97 3/20 0.47
CYP1A2 P05177 3/20 0.44
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 1/20 0.44
GRIN2D O15399 1/20 0.44
GRIN3B O60391 1/20 0.44
MAPK1 P28482 1/20 0.44
CYP2C19 P33261 1/20 0.44
AHR P35869 1/20 0.44
CHRNA7 P36544 1/20 0.44
KMT2A Q03164 1/20 0.44
GRIN1 Q05586 1/20 0.44
GRIN2A Q12879 1/20 0.44
GRIN2B Q13224 1/20 0.44
GRIN2C Q14957 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2469641 0.89 GLA (0.62) GLAGAAKDM4ECYP1A2MEN1
SCHEMBL12047086 0.83 SLC40A1 (0.43) GLAGAAKDM4EHPGDCYP1A2
SCHEMBL2475302 0.81 SLC40A1 (0.40) GLAGAAKDM4ECYP1A2MEN1
SCHEMBL2472983 0.80 SLC40A1 (0.41) GLAGAACYP1A2ALDH1A1ATM
SCHEMBL2475201 0.78 SLC40A1 (0.38) GLAGAAKDM4EHPGDTDP1
SCHEMBL2475206 0.78 SLC40A1 (0.38) GLAGAAKDM4EHPGDTDP1
SCHEMBL8460328 0.78 TP53 (0.48) GLAGAAKDM4EHPGDGPR35
SCHEMBL11384292 0.78 HPGD (0.46) GLAGAAKDM4EHPGDTDP1
SCHEMBL30054313 0.77 GAA (0.77) GLAGAAKDM4EHPGDTDP1
SCHEMBL12027694 0.76 GLA (0.54) GLAGAAKDM4EHPGDGPR35

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373650-B1 TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER NOSCIRA SA (ES) 2012-10-24 EP disclosed
WO-2010066832-A1 TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER NOSCIRA, S.A. (ES) 2010-06-17 WO disclosed
EP-2196466-A1 Triple substituted phenanthroline derivatives for the treatment of neurodegenerative or heamatological diseases or conditions NOSCIRA, S.A. (ES) 2010-06-16 EP disclosed